Skip to Content

    Lifesaving shortcuts in gene testing.

    The genomic sequencing giant has managed to spur personalized drug development, help foster a revolution in at-home DNA testing, and even save critically ill newborns. The company has been at the forefront of making whole genomic sequencing not just cheaper (it now costs less than $1,000 to conduct such sequencing, as opposed to the $3 billion it cost to sequence the first full human genome—largely thanks to Illumina’s work over the past 20 years)—but also considerably faster. 

    That’s absolutely critical when it comes to saving newborns in the ICU suffering from rare genetic disorders, according to Dr. Stephen Kingsmore, the CEO of Rady Children’s Institute for Genomic Medicine in San Diego. “Illumina is involved in every step of delivering care for these sick babies,” he says. Kingsmore says that, thanks to Illumina’s technology and dedication to making whole genomic sequencing accessible, affordable, and fast, a critically ill baby can have his or her genome sequenced in as little as 20 hours—which means that child can have personalized treatment delivered within a matter of days rather than weeks, likely spelling the difference between life and death. The Rady Institute has already tested about 1,000 sick newborns with Illumina’s tech in the past three years (about half of them in the past 12 months). 

    Fortune Data StoreLooking for leads, investment insights, or competitive intelligence?Get Premium Access

    Company Information

    Country
    U.S.
    Headquarters
    San Diego
    Impact Segment
    Public Health/Nutrition
    Sector
    Technology
    Industry
    Scientific, Photographic and Control Equipment
    CEO
    Francis deSouza
    Websitehttp://www.illumina.com
    Company Type
    Public
    Ticker
    ILMN
    Prior Year Rank-
    Revenues ($M) (Last Fiscal Year)$3,333
    Profits ($M) (Last Fiscal Year)$826
    Market Value ($M) as of 8/12/19$42,680
    Employees7,300

    Refinitiv Sustainable Leadership Monitor